Clinical trials: Gastrointestinal Reflux
Gastroesophageal Reflux, Heartburn
A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of patients with erosive or ulcerative gastroesophageal reflux disease (GERD) in routine primary health care.
- Trial name
- NCT00216489
- Testing
- rabeprazole sodium
- Volunteers
- 191 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Gastroesophageal Reflux Disease
A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece
The present study has been designed to provide current data on GERD prevalence in several regional areas of Greece outside the two major urban centres (Athens and Thessaloniki), to measure the treatment response in GERD patients…
- Trial name
- GERDQ-XS (NCT01215305)
- Where
- 19 sites in Greece
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms
The study is designed to assess the effect and safety of oral administration of VECAM 40/300 administered at bedtime compared to Esomeprazole 20 mg administered 30-60 minutes before dinner, for control of nighttime and daytime HB…
- Trial name
- NCT01059383
- Testing
- VECAM 40/300, Esomeprazole 20 mg
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Vecta Ltd.
Gastroesophageal Reflux in Children
Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)
The aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.
- Trial name
- STELLAR (NCT04358146)
- Testing
- Experimental Infant formula, Infant formula thickened with locust bean gum
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 346 people
- Sponsor
- United Pharmaceuticals
Gastrointestinal Disorder, Functional, Regurgitation, Gastric
Transition to Infant Formula Feeding on Gastrointestinal Regurgitation (TIGER) Study
To compare the frequency of regurgitation and other digestive outcomes between infants who receive an infant formula based on whole goat milk and an infant formula based on cow milk proteins during the transition period from…
- Conditions
- Gastrointestinal Disorder, Functional, Regurgitation, Gastric, Colic, Infantile, Constipation - Functional
- Trial name
- TIGER (NCT05363553)
- Testing
- Infant formula based on whole goat milk, infant formula based on cow milk proteins
- Where
- Thailand
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Dairy Goat Co-operative (N.Z.) Limited
Gastroesophageal Reflux
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)
The aim of the study is to evaluate the effect of pantoprazole on fast symptom reduction in hospitalized patients with NERD (non-erosive reflux disease) or GERD (gastroesophageal reflux disease, Los Angeles [LA] Grade A-D).
- Trial name
- NCT00326027
- Testing
- Pantoprazole
- Where
- 35 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Nycomed
Gastroesophageal Reflux Disease
A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation
The primary purpose of the study is to evaluate effect of Dexilant treatment among GERD participants in the Russian Federation.
- Trial name
- INTEGRO (NCT04311541)
- Sponsor
- Takeda
GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
The goal of this clinical trial is to investigate how well linaprazan glurate can maintain healed erosive esophagitis (EE) caused by GERD in participants who have participated in a prior healing trial, compared to lansoprazole…
- Trial name
- NCT07313774
- Testing
- Linaprazan glurate - High dose, Linaprazan glurate - Low dose, Lansoprazole - Marketed approved dose
- Sponsor
- Cinclus Pharma Holding AB
GERD
Asociación Española de Gastroenterologia (Spanish Gastroenterology Association) Gastroesophageal Reflux Disease Guideline - Prospective Study
To evaluate symptomatic outcome and HRQoL in GERD patients treated following a new CP Guideline.
- Trial name
- Prospect (NCT00697008)
- Where
- 29 sites in Spain
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)
The aim of this study is to evaluate the complete remission rates, endoscopic relapses, study discontinuation rates, and quality of life parameters in patients with erosive GERD.
- Trial name
- NCT00325676
- Testing
- Pantoprazole
- Where
- 45 sites in Brazil, Germany and 2 more
- Volunteers
- 639 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease (GERD), Heartburn
Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with Secretol 80/80 versus Nexium 40 mg daily.
- Conditions
- Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
- Trial name
- NCT01129713
- Testing
- Secretol, Nexium
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Effexus Pharmaceutical
Gastroesophageal Reflux
Validation of RDQ Questionnaire
The primary objective of this study is to determine the accuracy of the Reflux Disease Questionnaire (RDQ) as a diagnostic test for gastroesophageal reflux disease.
- Trial name
- NCT00291746
- Testing
- Esomeprazole, Bravo technique
- Where
- 30 sites in Canada, Denmark and 4 more
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
GERD
National Survey on Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this observational study is to assess the impact of abdominal fat on severity and frequency of GERD symptoms .
- Trial name
- LINEA (NCT00695838)
- Where
- 1,624 sites in France
- Volunteers
- 5,084 people
- Sponsor
- AstraZeneca
Gastro Esophageal Reflux
Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment
This is a post-market, multi-center, double-blind, placebo-controlled, randomized, cross-over study with GERDOff Plus added on top of the current PPI treatment in patients with GERD.
- Trial name
- NCT04202692
- Testing
- Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- SOFAR S.p.A.
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux disease (eGERD).
- Trial name
- NCT00658632
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 85 sites in United States
- Volunteers
- 1,397 people
- Sponsor
- Eisai Inc.
Gastro Esophageal Reflux Disease
Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance
Study Hypothesis: This study is designed as an integral part of the development of new or improved features or components of the Bravo® pH Monitoring System and may serve verification and validation purposes The study population…
- Trial name
- NCT01503476
- Testing
- Bravo® pH Monitoring System
- Where
- Israel
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Reflux Episodes
14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations
The purpose of the study is to assess the safety and tolerability of AZD2066 and to explore the effect of a single dose of AZD2066 on the function of the cardia (the opening between the stomach and the esophagus) compared to…
- Trial name
- NCT00813306
- Testing
- AZD2066
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Reflux Disease
AZD3355 Dose-escalation Study in Healthy Males
The aim is to establish the maximal tolerated dose of AZD3355 for the selection of doses in the up-coming studies. This will be done by comparing single and repeated doses of AZD3355 to placebo ("inactive substance").
- Trial name
- NCT00757419
- Testing
- AZD3355
- Where
- Sweden
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects
The purpose of this study is to investigate the pharmacodynamics (PD) and pharmacokinetics of E3710 following oral administration to Healthy Male Japanese Subjects
- Trial name
- NCT01390714
- Testing
- E3710
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Gastroesophageal Reflux
Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease…
- Trial name
- NCT02030925
- Testing
- IW-3718
- Where
- 10 sites in United States
- Volunteers
- 93 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.